Celltrion has passed the final gate to the merger
김지선
stockmk2020@alphabiz.co.kr | 2023-11-15 06:41:44
[Alpha Biz=(Chicago) Reporter Kim Jisun] Celltrion Group announced on the 14th that the total amount of stock purchase claims for the merger between Celltrion and Celltrion Healthcare totaled 7.9 billion won.
The number of shares tallied by the exercise of stock purchase claims is 41,972 shares of Celltrion (about 6.3 billion won) and 23,786 shares of Celltrion Healthcare (about 1.6 billion won), respectively. Based on the total number of shares of both companies, the stock purchase claim was far below expectations, accounting for only 0.19% of the total number of shares opposed to the merger. The limit initially proposed by the company was worth KRW 1 trillion.
Seo Jung-jin, honorary chairman of Celltrion Group, earlier vowed to secure direct investment funds and digest all stock purchase claims even if the exercise of stock purchase claims exceeds KRW 1 trillion. The two companies, Celltrion and Celltrion Healthcare, announced plans to purchase additional shares worth 300 billion won after purchasing treasury stocks worth 55295 billion won by the 7th of this month.
The merged Celltrion is expected to focus on full-fledged growth after its launch on Dec. 28 while reducing its financial burden. If the listing of new shares is carried out on Jan. 12 next year, the merger between the two companies will be completed.
[ⓒ AlphaBIZ. 무단전재-재배포 금지]
많이 본 기사
- 1Samsung Electronics Labor Talks Collapse Again as Union Rejects “Industry-Leading” Compensation Proposal
- 2Korea Exchange Flags 76 Suspected Short-Selling Violations via Monitoring System
- 3Affinity Equity Partners Seeks Price Cut in Lotte Rental Deal Amid Antitrust Hurdles
- 4Naver Revises Dormant Account Policy for Mail Service to Cut Costs and Reduce Spam Traffic
- 5Court Dismisses Shareholder Derivative Suit Against DB HiTek Chairman Family Over Compensation Dispute
- 6Naphtha Supply Risks Trigger Packaging Shortage Concerns Across Food and Restaurant Industries